This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IDEX Q2 Earnings Surpass Estimates, Sales Increase Year Over Year
by Zacks Equity Research
IEX tops Q2 estimates with 7% revenue growth, driven by acquisitions and strong HST performance, but margins slipped.
Idex (IEX) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Idex (IEX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Idex (IEX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Idex (IEX) delivered earnings and revenue surprises of +3.50% and +0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Stanley Black's Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
SWK crushed Q2 earnings estimates but saw 2% revenue dip as segment softness and margin pressure weighed on results.
IDEX Gears Up to Post Q2 Earnings: Is a Beat in the Offing?
by Zacks Equity Research
IEX is likely to extend its earnings beat streak as strong HST and FSDP demand offsets FMT softness and rising costs.
Graco's Earnings Miss Estimates in Q2, Sales Increase Y/Y
by Zacks Equity Research
GGG misses Q2 earnings and revenue estimates, but posts 3% sales growth driven by EMEA and Asia Pacific gains.
Chart Industries (GTLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Chart Industries (GTLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Idex (IEX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Idex (IEX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Idex (IEX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Idex (IEX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IDEX Stock Exhibits Strong Prospects Despite Persisting Headwinds
by Zacks Equity Research
IEX is set to benefit from the solid momentum across its FSDP & FMT segments. However, increasing expenses remain a concern.
IDEX Q1 Earnings Surpass Estimates, Sales Increase Year Over Year
by Zacks Equity Research
Strength in the Health & Science Technologies segment aids IEX's first-quarter results.
Idex (IEX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Idex (IEX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Idex (IEX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Idex (IEX) delivered earnings and revenue surprises of 6.71% and 1.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Idex (IEX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Idex (IEX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Idex (IEX) Soars 7.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Idex (IEX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IDEX Stock Gains From Business Strength, Headwinds Persist
by Zacks Equity Research
IEX benefits from strength in its Fluid & Metering Technologies segment, acquisitions and shareholder-friendly policies. However, rising costs and expenses are concerning.
LiqTech International, Inc. (LIQT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
LiqTech International (LIQT) delivered earnings and revenue surprises of -5.41% and 10.37%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain IDEX Stock in Your Portfolio Now
by Zacks Equity Research
IEX gains from strength across its Fluid & Metering segment, acquired businesses and shareholder-friendly policies. However, rising operating expenses are concerning.
IDEX Q4 Earnings Surpass Estimates, Sales Increase Year Over Year
by Zacks Equity Research
Strength in the Fire & Safety/Diversified Products segment aids IEX's fourth-quarter results.
Compared to Estimates, Idex (IEX) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Idex (IEX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Idex (IEX) Tops Q4 Earnings Estimates
by Zacks Equity Research
Idex (IEX) delivered earnings and revenue surprises of 0.49% and 0.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
IDEX Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Strength in the FMT and FSDP segments and accretive acquisitions are likely to aid IEX's fourth-quarter results.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
IDEX Stock Exhibits Strong Prospects Despite Persisting Headwinds
by Zacks Equity Research
IEX is set to benefit from solid momentum across its FSDP & FMT segments. However, increasing expenses remain a concern.
Symbiotic Stock Plunges 48% YTD: How Should Investors Play?
by Arghyadeep Bose
Given the recent decline in SYM's share price, we analyze its current position to determine whether investors should buy, hold or sell the stock.